Pneumococcal Pneumonia

Preventing Pneumococcal Pneumonia in Older Adults

The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) is an industry-sponsored (Pfizer) trial with the primary objective of showing the efficacy of a polysaccharide conjugate vaccine (PCV13) in preventing pneumococcal pneumonia in adults. This randomized, placebo-controlled, double-blind trial took place in The Netherlands, where pneumococcal vaccine is not routinely recommended for use in older adults, so the participants had never received a pneumonia vaccine. Participants were older than 65 years and primarily white, and about 50% were men.

Bangladeshi children to receive two new vaccines

Children in Bangladesh are to regularly receive a pneumococcal vaccine (PCV) and an Inactivated Polio Vaccine (IPV) that are being added to the country’s national immunization program.
These introductions will benefit more than 3 million children. PCV defends children against pneumococcal pneumonia, and the IPV vaccine fulfills the Polio Eradication & Endgame Strategic Plan 2013-2018.

Pfizer publishes pneumonia immunization trial results

Pfizer Inc. recently published its findings from the company’s Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).
The study determined the efficiency of the Prevenar 13 vaccine in preventing a vaccine-type pneumococcal community-acquired pneumonia (CAP) in a first episode. The study included both non-bacteremic and non-invasive CAP and vaccine-type invasive pneumococcal disease (IPD).
The study involved subjects 65 years and older.

Pfizer gains EU approval for pneumococcal vaccine

The European Commission recently granted an expanded indication for Pfizer, Inc.’s Prevenar 13 to vaccinate adults for pneumonia caused by the 13 pneumococcal serotypes contained in the vaccine.
The approval means that the vaccine can now be administered to adults 18 years and older in Europe.

MSF bends donation policy for pneumonia vaccine

After years of refusing vaccine handouts from big pharmaceutical companies, international medical humanitarian group Médecins Sans Frontières is bending its policy to accept donations of the pneumococcal conjugate vaccine.

Afrique: agir ensemble contre la pneumonie

Nous célébrons aujourd'hui la Journée de mondiale de la pneumonie, une maladie qui tue plus d'un million d'enfants chaque année. Tout enfant, où qu'il naisse, mérite d'avoir la possibilité de vivre une vie saine et de réaliser son potentiel.
Il ne s'agit pas seulement d'un droit individuel mais d'un fondement indispensable pour créer des sociétés saines et fortes. Offrir à nos enfants une base solide permet de briser le cercle de la pauvreté qui entrave la croissance des communautés et des pays.

Record numbers of children protected against leading causes of pneumonia with Gavi support

More children than ever before are being protected against the leading causes of pneumonia as countries strengthen their immunisation programmes with support from Gavi, the Vaccine Alliance.
In 2013 alone, almost 40 million children in developing countries received the pentavalent vaccine, which includes protection against Haemophilus Influenzae type b (Hib) pneumonia, while 15 million children were immunised with pneumococcal conjugate vaccine (PCV).

17th International Congress on Infectious Diseases

Organized and hosted by the International Society for Infectious Diseases (ISID)

From the ISID website



From the US Centers for Disease Control and Prevention (US CDC) website: